Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Autor: Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frølund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Støve Bødker, Anne Stidsholt Roug, Martin Bøgsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkær

Publikováno v: BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)

Abstract Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called m

Externí odkaz: https://doaj.org/article/5436faba1b7640768aa73dd91ad91f57

High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003–2007

Autor: Piotr Kozlowski, Maria Åström, Lucia Ahlberg, Per Bernell, Erik Hulegårdh, Hans Hägglund, Karin Karlsson, Alicja Markuszewska-Kuczymska, Beata Tomaszewska-Toporska, Bengt Smedmyr, Helene Hallböök

Publikováno v: Haematologica, Vol 97, Iss 9 (2012)

Background A minority of patients with adult acute lymphoblastic leukemia who relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation in patients in secon

Externí odkaz: https://doaj.org/article/b47cd69e243e4bfcb5252925072e1fed

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma

Autor: Astrid Gruber, Markus Hansson, Agneta Swedin, Johan Lund, Gösta Gahrton, Adil Doganay Duru, Lucia Ahlberg, Anders Waage, Ulf-Henrik Mellqvist, Peter Gimsing, Birgitta Lauri, Mats Hardling, Ulf Christian Frølund, Karin Forsberg, Erik Holmberg, Evren Alici, Conny Carlsson, Hareth Nahi, Annette Juul Vangsted, Cecilie Blimark

Publikováno v: Cancer Medicine
Lund, J, Gruber, A, Lauri, B, Duru, A D, Blimark, C, Swedin, A, Hansson, M, Forsberg, K, Ahlberg, L, Carlsson, C, Waage, A, Gimsing, P, Vangsted, A J, Frølund, U, Holmberg, E, Gahrton, G, Alici, E, Hardling, M, Mellqvist, U-H & Nahi, H 2018, ' Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma ', Cancer Medicine, vol. 7, no. 6, pp. 2256-2268 . https://doi.org/10.1002/cam4.1422

Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single‐agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21ef9d77483e4100720ccbffe38d32a6
http://europepmc.org/articles/PMC6010717

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial

Autor: Evren Alici, Johan Lund, Conny Carlsson, Cecilie Blimark, Hareth Nahi, Astrid Gruber, Ulf-Henrik Mellqvist, Ingrid Jakobsen Falk, Agneta Swedin, Kourosh Lotfi, Lucia Ahlberg, Mats Hardling, Karin Forsberg, Henrik Gréen, Birgitta Lauri

Publikováno v: Cancer Chemotherapy and Pharmacology

Purpose Despite therapeutic advances, patients with multiple myeloma (MM) continue to experience disease relapse and treatment resistance. The gene ABCB1 encodes the drug transporter P-glycoprotein, which confers resistance through drug extrusion acr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6d35274f2e447d1fafc6837f9e2badb
https://doi.org/10.1007/s00280-017-3481-8

Survival in adult acute lymphoblastic leukaemia (ALL) : A report from the Swedish ALL Registry

Autor: Lucia Ahlberg, Hege Garelius, Erik Hulegårdh, Andreea Moicean, Piotr Kozlowski, Karin Karlsson, Emma Bergfelt Lennmyr, Antonio Santamaria Izarra, Beata Tomaszewska-Toporska, Anna Lübking, Helene Hallböök, Joel Joelsson

Publikováno v: European Journal of Haematology

Objectives As new, effective therapies emerge for acute lymphoblastic leukaemia (ALL), the results of clinical trials need to relate to standard of care. Methods We used the population-based Swedish ALL Registry to evaluate characteristics, treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45ad365de408231994163506c9ed67e
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-390495